Pristinamycin versus oxacillin in the treatment of superficial pyoderma. Multicentric, randomized study in 293 outpatients;Pristinamycine (Pyostacine 500®) versus Oxacilline (Bristopen®) dans le traitement des pyodermites superficielles. Etude randomisee multicentrique chez 293 malades ambulatoires

Annales de Dermatologie et de Venereologie

Volumn 124, Issue 5, 1997, Pages 384-389

  Bernard, P ^a   Vaillant, L ^a   Martin, Ch ^a   Beylot, C ^a   Quentin, R ^a   Touron, D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXACILLIN; PLACEBO; PRISTINAMYCIN; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE; VIRGINIAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTPATIENT; PYODERMA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TOPICAL DRUG ADMINISTRATION; COMPARATIVE STUDY; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXACILLIN; PENICILLINS; PYODERMA; VIRGINIAMYCIN;

EID: 0030609194     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Demidovich C.W., Wittler R.R., Ruff M.E., Bass J.W., Browning W.C. Impetigo-current etiology and comparison of penicillin, erythromycin and cephalexin therapies. Am. J. Dis. Child 1990;144:1313-5.
2. Highet A.S., Hay R.J., Roberts S.O.B. Bacterial infections. In: Textbook of Dermatology, Rook/Wilkinson/Ebling. Blackwell Scientific Publications, 1992:965-8.
3. Darmstadt G.L., Lane A.T. Impetigo: an overviwe. Pediatr. Dermatol, 1994;11:293-303.
4. Shriner D.L., Schwartz R.A., Janniger C.K. Impetigo. Cutis 1995;56:530-2.
5. Dahl M.V. Strategies for the management of recurrent furunculosis. South. Med. J. 1987;80:352-6.
6. Elbaze P., Ortonne J.P. Furonculose chronique. Ann. Dermatol. Venereol. 1988;115:859-64.
7. Carruthers R. Prescribing antibiotics for impetigo. Drugs 1988;36:364-9.
8. Sheagren J.N. Treatment of skin and skin structure infections in patients at risk. Am. J. Med. 1984;76:180-6.
9. Feingold D.S., Wagner R.F. Jr. Antibacterial therapy. J. Am. Acad. Dermatol. 1986;14:535-48.
10. Barton L.L., Friedman A.D., Portilla M.G. Impetigo contagiosa: a comparison of erythromycin and dicloxacillin therapy. Pediatr. Dermatol. 1988;5:88-91.
11. Denis F., Dabernat H. et le Groupe d'Etude Multicentrique. Activités comparées de la pristinamycine et de 11 antibiotiques. Etude multicentrique portant sur les bactéries du spectre des streptogramines. Concours Med. 1992;114:2293-8.
12. Autuly F., Plessis P., Vaucel J., Pouedral P., Avril J.L. Répartition des phénotypes macrolides-lincosamides-streptogramines chez Staphylococcus aureus et Staphylococcus epidermidis et leur sensibilité à la pristinamycine. Med. Mal. Infect. 1995;25:985-90.
13. Bastin R., Rapin M., Kernbaum S. Etude clinique de l'activité anti-staphylococcique de la pristinamycine et de l'oxacilline. Pathol. Biol. 1982;30:473-5.
14. Bernard P., Risse L., Bonnetblanc J.M. Traitement des dermohypodermites aiguës bactériennes de l'adulte par la pristinamycine: étude ouverte chez 42 malades. Ann. Dermatol. Venereol. 1996;123:16-20.
15. Brunel D., Jeanmougin M. Efficacité de la pristinamycine au cours des infections cutanées bactériennes. Résultats d'un essai thérapeutique mené par des médecins praticiens de ville. Infectiologie 1987;18:34-42.
16. Machel L., Puissant A., Vaillant L. et le Groupe d'études des infections cutanées. Essai comparatif de l'acide fusidique comprimés à deux posologies (500 mg et l g/jour) versus pristinamycine (2 g/jour) dans le traitement des infections cutanées. Nouv. Dermatol. 1994;13:520-4.
17. Christensen O.B., Anehus S. Hydrogen peroxyde cream: an alternative to topical antibiotics in the treatment of impetigo contagiosa. Acta. Derm. Venereol. (Stockh) 1994;74:460-2.
18. Mertz P.M., Marshall D.A., Eaglstein W.H., Piovanetti Y., Montalvo J. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch. Dermatol. 1989;125:1069-73.
19. Goldfarb J., Crenshaw D., O'Horo J., Lemon E., Blumer J.L. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob. Agents Chemother. 1988;32:1780-7.
20. Gilbert M. Topical 2 p. 100 versus 2p. 100 fusidic acid ointment in the treatment of primary and secondary skin infections. J. Am. Acad. Dermatol. 1989;20:1083-7.
21. Barton L.L., Friedman A.D., Sharkey A.M., Schneller D.J., Swierkosz E.M. Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr. Dermatol. 1986;6:134-8.
22. Kobayashi S., Ikeda T., Okada H., Suzuki Y., Ishii M., Ohtake T., Oda T., Hishida A. Endemic occurence of glomerulonephritis associated with streptococcal impetigo. Am. J. Nephrol 1995;15:356-60.
23. Zafar A.B., Butler R.C., Reese D.J., Gaydos L.A., Mennonna P.A. Use of 3 p. 100 triclosan (Bacti-Stat®) to eradicate an outbreak of methieillin-resistant Staphylococcus aureus in a neonatal nursery. Am. J. Infect. Control. 1995;23:200-8.
24. Zimanoff J., Rosdahl V.T., Petersen W., Scheibel J. Recurrent staphylococcal furunculosis in families. Scand. J. Infect. Dis. 1988;20:403-5.